MiR-663b has been demonstrated to be abnormally expressed in several cancer types and was involved in the progression of cancer. Although overexpression of miR-663b in colorectal cancer was observed, the role of miR-663b in colorectal cancer cells has not been identified yet. In this study, we analyzed expression of miR-663b in colorectal tumors and explored the molecular mechanism of miR-663b in colorectal cancer cells. MiR-663b was significantly overexpressed in colorectal tumors and cell lines. Downregulation of miR-663b inhibited cell proliferation and sphere forming ability in colorectal cancer cells. In addition, miR-663b downregulation inactivated Ras/Raf signaling activity and subsequently decreased YAP1 and CD44 expression in colorectal cancer cells. Using TargetScan software, TNK1, a negative regulator of Ras/Raf signaling, was predicted to be a target gene of miR-663b. Western blotting and RT-qPCR showed that TNK1 expression was negatively regulated by miR-663b. In addition, the direct binding of miR-663b to TNK1 mRNA was proved by dual luciferase reporter assay. Furthermore, downregulation of miR-663b inhibited colorectal cancer cell proliferation and stemness, which was reversed after siRNA-mediated silencing of TNK1. In conclusion, the current study revealed a pivotal role of miR-663b in the progression of colorectal cancer.
microR-663b TNK1 Colorectal cancer
This is a preview of subscription content, log in to check access.
SH, ZY and HW participated in the design and performance of the experiments; SH, ZY, HW, YS and MB contributed to the collection of samples and clinical data; ZY and HW analyzed the data; HW and LD supervised and wrote the manuscript.
Compliance with ethical standards
Conflict of interest
We declare that we have no conflict of interest in the current study.
All procedures performed in studies involving human participants were in accordance with the ethical standards of The First Hospital of Jilin University (No. FHJU20120603) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.CrossRefGoogle Scholar
Siveen KS, Raza A, Ahmed EI, et al. The role of extracellular vesicles as modulators of the tumor microenvironment, metastasis and drug resistance in colorectal cancer. Cancers (Basel). 2019;11:746.CrossRefGoogle Scholar
Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10:717–28.CrossRefGoogle Scholar
Chen D, Gu K, Wang H. Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies. Cancer Manag Res. 2019;11:1705–16.CrossRefGoogle Scholar
Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000;351(Pt 2):289–305.CrossRefGoogle Scholar
Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459–65.CrossRefGoogle Scholar
Jiang H, Wu L, Chen J, et al. Sulfiredoxin promotes colorectal cancer cell invasion and metastasis through a novel mechanism of enhancing EGFR signaling. Mol Cancer Res. 2015;13:1554–66.CrossRefGoogle Scholar
Klampfer L, Swaby LA, Huang J, Sasazuki T, Shirasawa S, Augenlicht L. Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis. Oncogene. 2005;24:3932–41.CrossRefGoogle Scholar
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.CrossRefGoogle Scholar
Hoare K, Hoare S, Smith OM, Kalmaz G, Small D, Stratford May W. Kos1, a nonreceptor tyrosine kinase that suppresses Ras signaling. Oncogene. 2003;22:3562–77.CrossRefGoogle Scholar
Hoehn GT, Stokland T, Amin S, et al. Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38-stem/progenitor cells. Oncogene. 1996;12:903–13.PubMedGoogle Scholar
Hoare S, Hoare K, Reinhard MK, Lee YJ, Oh SP, May WS Jr. Tnk1/Kos1 knockout mice develop spontaneous tumors. Cancer Res. 2008;68:8723–32.CrossRefGoogle Scholar
Kavitha N, Vijayarathna S, Jothy SL, et al. MicroRNAs: biogenesis, roles for carcinogenesis and as potential biomarkers for cancer diagnosis and prognosis. Asian Pac J Cancer Prev. 2014;15:7489–97.CrossRefGoogle Scholar
Hausser J, Zavolan M. Identification and consequences of miRNA-target interactions–beyond repression of gene expression. Nat Rev Genet. 2014;15:599–612.CrossRefGoogle Scholar
Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development. 2005;132:4653–62.CrossRefGoogle Scholar
Liu F, Di Wang X. miR-150-5p represses TP53 tumor suppressor gene to promote proliferation of colon adenocarcinoma. Sci Rep. 2019;9:6740.CrossRefGoogle Scholar
You Q, Li H, Liu Y, et al. MicroRNA-650 targets inhibitor of growth 4 to promote colorectal cancer progression via mitogen activated protein kinase signaling. Oncol Lett. 2018;16:2326–34.PubMedPubMedCentralGoogle Scholar
Xie HH, Huan WT, Han JQ, Ren WR, Yang LH. MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2. Biol Res. 2019;52:18.CrossRefGoogle Scholar
Wang N, Zeng L, Li Z, Zhen Y, Chen H. Serum miR-663 expression and the diagnostic value in colorectal cancer. Artif Cells Nanomed Biotechnol. 2019;47:2650–3.CrossRefGoogle Scholar
Lee SA, Kwon HC, Park MA, et al. Impact of the new AJCC staging system and adjuvant treatment in rectal cancer. Cancer Res Treat. 2004;36:121–7.CrossRefGoogle Scholar
Mizukami T, Izawa N, Nakajima TE, Sunakawa Y. Targeting EGFR and RAS/RAF signaling in the treatment of metastatic colorectal cancer: from current treatment strategies to future perspectives. Drugs. 2019;79:633–45.CrossRefGoogle Scholar
Qian F, Xiao J, Gai L, Zhu J. HMGB1-RAGE signaling facilitates Ras-dependent Yap1 expression to drive colorectal cancer stemness and development. Mol Carcinog. 2019;58:500–10.CrossRefGoogle Scholar
Hofmann M, Rudy W, Gunthert U, et al. A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res. 1993;53:1516–21.PubMedGoogle Scholar
Carden T, Singh B, Mooga V, Bajpai P, Singh KK. Epigenetic modification of miR-663 controls mitochondria-to-nucleus retrograde signaling and tumor progression. J Biol Chem. 2017;292:20694–706.CrossRefGoogle Scholar
Zang W, Wang Y, Wang T, et al. miR-663 attenuates tumor growth and invasiveness by targeting eEF1A2 in pancreatic cancer. Mol Cancer. 2015;14:37.CrossRefGoogle Scholar
Shi Y, Chen C, Yu SZ, et al. miR-663 suppresses oncogenic function of CXCR28 in glioblastoma. Clin Cancer Res. 2015;21:4004–13.CrossRefGoogle Scholar
Huang Y, Liu J, Fan L, et al. miR-663 overexpression induced by endoplasmic reticulum stress modulates hepatocellular carcinoma cell apoptosis via transforming growth factor beta 1. Onco Targets Ther. 2016;9:1623–33.CrossRefGoogle Scholar
Fiori ME, Villanova L, Barbini C, De Angelis ML, De Maria R. miR-663 sustains NSCLC by inhibiting mitochondrial outer membrane permeabilization (MOMP) through PUMA/BBC3 and BTG2. Cell Death Dis. 2018;9:49.CrossRefGoogle Scholar
Liang S, Zhang N, Deng Y, et al. miR-663b promotes tumor cell proliferation, migration and invasion in nasopharyngeal carcinoma through targeting TUSC2. Exp Ther Med. 2017;14:1095–103.CrossRefGoogle Scholar
Wang M, Jia M, Yuan K. MicroRNA-663b promotes cell proliferation and epithelial mesenchymal transition by directly targeting SMAD7 in nasopharyngeal carcinoma. Exp Ther Med. 2018;16:3129–34.PubMedPubMedCentralGoogle Scholar
Chen J, Song B, Kong G. MicroRNA663b downregulation inhibits proliferation and induces apoptosis in bladder cancer cells by targeting TUSC2. Mol Med Rep. 2019;19:3896–902.PubMedGoogle Scholar
Ma L, Wang L, Shan Y, et al. Suppression of cancer stemness by upregulating Ligand-of-Numb protein X1 in colorectal carcinoma. PLoS ONE. 2017;12:e0188665.CrossRefGoogle Scholar
May WS, Hoare K, Hoare S, Reinhard MK, Lee YJ, Oh SP. Tnk1/Kos1: a novel tumor suppressor. Trans Am Clin Climatol Assoc. 2010;121:281–92 (discussion 92-3).PubMedPubMedCentralGoogle Scholar